Angioedema News and Research

RSS
Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis.
Shire announces third quarter 2009 financial results

Shire announces third quarter 2009 financial results

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Dyax reports financial results for third quarter 2009; attracts a net loss of $0.17 per share

Dyax reports financial results for third quarter 2009; attracts a net loss of $0.17 per share

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from efficacy study of CIMZIA in Crohn's disease patients presented

FDA approves Berinert for adults and adolescents with HAE

FDA approves Berinert for adults and adolescents with HAE

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

FDA approves Berinert for the treatment of hereditary angioedema

FDA approves Berinert for the treatment of hereditary angioedema

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough receives FDA recommendation approval for PEGINTRON

Pharming announces EUR 20 million SEDA extension with YA Global

Pharming announces EUR 20 million SEDA extension with YA Global

Offer period for conversion of bonds extended by Pharming

Offer period for conversion of bonds extended by Pharming

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Dyax to present an update of its clinical development programs

Dyax to present an update of its clinical development programs

Biotech company Pharming Group receives confirmation of validation for Rhucin

Biotech company Pharming Group receives confirmation of validation for Rhucin

Public offer to holders of Pharming Group's convertible bonds

Public offer to holders of Pharming Group's convertible bonds

DNage's observational study assesses natural progression of CS in children

DNage's observational study assesses natural progression of CS in children